Microdosing for early biokinetic studies in humans

Radiation Protection Dosimetry

Volumn 139, Issue 1-3, 2010, Pages 348-352

  Stenstrom K ^a   Sydoff, M ^b   Mattsson, S ^b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG;

ANIMAL; ARTICLE; BLOOD; BLOOD ANALYSIS; DOSE CALCULATION; HUMAN; KINETICS; MASS SPECTROMETRY; METABOLIC CLEARANCE RATE; METHODOLOGY; PHARMACOKINETICS;

ANIMALS; BLOOD CHEMICAL ANALYSIS; DRUG DOSAGE CALCULATIONS; HUMANS; KINETICS; MASS SPECTROMETRY; METABOLIC CLEARANCE RATE; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 77953353160     PISSN: 01448420     EISSN: None     Source Type: Journal    
DOI: 10.1093/rpd/ncq029     Document Type: Article

References (15)

1. DiMasi, A. Risks in new drug development: approval, success rates for investigational drugs. Clin. Pharm. Ther. 69, 297-307 (2001).
2. Lappin, G. and Garner, R. C. Big physics, small doses - the use of AMS and PET in human microdosing of development drugs. Nat. Rev. Drug Discov. 2, 233-240 (2003).
3. Garner, R. C. and Lappin, G. The phase 0 microdosing concept. Br. J. Clin. Pharmacol. 61(4), 367-370 (2006).
4. European Medicines Agency. Position paper on nonclinical safety studies to support clinical trials with a single microdose, CPMP/SWP/2599 (2004).
5. Center for Drug Evaluation and Research. Guidance for industry, investigators and reviewers: exploratory IND studies. Draft guidance (US Dep. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research) (2004).
6. Combes, R. D., Berridge, T., Connelly, J., Eve, M. D., Garner, R. C., Toon, S. and Wilcox, P. Early microdose drug studies in human volunteers can minimise animal testing: proceedings of a workshop organised by Volunteers in Research and Testing. Eur. J. Pharm. Sci. 19, 1-11 (2003).
7. Lappin, G. and Garner, R. C. The utility of microdosing over the past 5 years. Expert Opin. Drug Metab. Toxicol. 4(12), 1499-1506 (2008).
8. EUMAPP document. Outcomes from EUMAPP - a study comparing and pharmacological pharmacokinetics. www.eumapp.com (2009).
9. Fifield, L. K. Accelerator mass spectrometry and its applications. Rep. Phys. Prog. 62, 1223-1274 (1999).
10. Skog, G. The single stage AMS machine at Lund University: Status Report. Nucl. Instr. Meth. B259, 1-6 (2007).
11. Getachew, G., Kim, S.-H., Burri, B. J., Kelly, P. B., Haack, K. W., Ognibene, T. J., Buchholz, B. A., Vogel, J. S., Modrow, J. and Clifford, A. J. How to convert biological carbon into graphite for AMS. Radiocarbon 48(3), 325-336 (2006).
12. 14C sample preparation for AMS microdosing studies at Lund University with on-line combustion and septa-sealed vials. Nucl. Instr. Meth. B. doi:10.1016/j.nimb.2009.10.065 (2009).
13. Schulze-Konig, T. U., Synal, H.-A., Suter, M., Dueker, S. R. and Vuong, L. T. BioMICADAS: compact next generation AMS system for pharmaceutical science. In: 11th International Conference on Accelerator Mass Spectrometry, Rome, Italy, 14-19 September 2008 (2008) (Book of Abstracts).
14. Ruff, M., Gaggeler, H. W., Hajdas, I., Suter, M., Synal, H.-A., Szidat, S. and Wacker, L. Radiocarbon measurements of small samples with the MICADAS gas ion source. In: 11th International Conference on Accelerator Mass Spectrometry, Rome, Italy, 14-19 September 2008 (2008) (Book of Abstracts).
15. 14C analysis with subattomole sensitivity. Anal. Chem. 80, 4820-4824 (2008).